(2HRA) H&R GmbH & Co. KGaA - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A2E4T77
2HRA EPS (Earnings per Share)
2HRA Revenue
2HRA: Chemicals, Lubricants, Plastics, Petroleum, Specialties
H&R GmbH & Co. KGaA is a global manufacturer and supplier of specialty chemicals and precision plastic parts, operating across Europe, Africa, Asia, and beyond. The companys diversified product portfolio caters to various industries, including pharmaceuticals, automotive, medical technology, and construction. With a rich history dating back to 1919, H&R has established itself as a reliable partner for businesses seeking high-quality chemical-pharmaceutical raw materials and custom-molded plastic components.
The companys business is structured around three key segments: ChemPharm Refining, ChemPharm Sales, and Plastics. ChemPharm Refining is responsible for producing a range of crude oil-based specialty products, including paraffins, white oils, and lubricants, while ChemPharm Sales focuses on distributing these products to various industries. The Plastics segment, meanwhile, develops and manufactures precision plastic parts and components for demanding applications, such as medical consumables and automotive components.
Analyzing the companys
By combining the insights from
To validate this forecast, it is essential to monitor H&Rs future earnings reports, industry trends, and macroeconomic factors that may impact the demand for its products. A thorough analysis of the companys financials, management decisions, and competitive positioning will be crucial in determining whether the predicted price target can be achieved.
Additional Sources for 2HRA Stock
2HRA Stock Overview
Market Cap in USD | 211m |
Sector | Basic Materials |
Industry | Specialty Chemicals |
GiC Sub-Industry | Commodity Chemicals |
IPO / Inception |
2HRA Stock Ratings
Growth Rating | -17.4 |
Fundamental | 7.34 |
Dividend Rating | 21.9 |
Rel. Strength | 5.04 |
Analysts | - |
Fair Price Momentum | 5.06 EUR |
Fair Price DCF | 8.78 EUR |
2HRA Dividends
Dividend Yield 12m | 2.32% |
Yield on Cost 5y | 2.03% |
Annual Growth 5y | 0.00% |
Payout Consistency | 47.5% |
Payout Ratio | 33.7% |
2HRA Growth Ratios
Growth Correlation 3m | 71.2% |
Growth Correlation 12m | 12.5% |
Growth Correlation 5y | -66.2% |
CAGR 5y | 0.09% |
CAGR/Max DD 5y | 0.00 |
Sharpe Ratio 12m | -0.09 |
Alpha | -0.78 |
Beta | 0.068 |
Volatility | 18.49% |
Current Volume | 21.9k |
Average Volume 20d | 11.1k |
As of June 24, 2025, the stock is trading at EUR 4.94 with a total of 21,935 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +1.21%, over three months by +20.01% and over the past year by +3.71%.
Neither. Based on ValueRay´s Fundamental Analyses, H&R GmbH & Co. KGaA is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.34 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of 2HRA is around 5.06 EUR . This means that 2HRA is currently overvalued and has a potential downside of 2.43%.
H&R GmbH & Co. KGaA has no consensus analysts rating.
According to our own proprietary Forecast Model, 2HRA H&R GmbH & Co. KGaA will be worth about 5.5 in June 2026. The stock is currently trading at 4.94. This means that the stock has a potential upside of +10.73%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 5.2 | 5.3% |
Analysts Target Price | - | - |
ValueRay Target Price | 5.5 | 10.7% |